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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYThe effective osteogenic commitment of human bone marrow mesenchymal stem cells (hBMSCs) is critical for bone regenerative ther-
apies. Extracellular vesicles (EVs) derived from hBMSCs have a regenerative potential that has been increasingly recognized. Herein, the
osteoinductive potential of osteogenically induced hBMSC-EVs was examined. hBMSCs secreted negatively charged nanosized vesicles
(35 nm) with EV-related surface markers. The yield of EVs over 7 days was dependent on an osteogenic stimulus (standard chemical
cocktail or RUNX2 cationic-lipid transfection). These EVs were used to sequentially stimulate homotypic uncommitted cells during
7 days, matching the seeding density of EV parent cells, culture time, and stimuli. Osteogenically committed hBMSC-EVs induced an
osteogenic phenotype characterized by marked early induction of BMP2, SP7, SPP1, BGLAP/IBSP, and alkaline phosphatase. Both EV
groups outperformed the currently used osteoinductive strategies. These data show that naturally secreted EVs can guide the osteogenic
commitment of hBMSCs in the absence of other chemical or genetic osteoinductors.INTRODUCTION
Human bone marrow mesenchymal stem cells (hBMSCs)
are attractive candidates for advanced cell therapies,
including bone regeneration (Costa-Pinto et al., 2012).
Satisfactory treatments are hampered by the difficulty in
obtaining a well-defined population of terminally differen-
tiated cells. This causes heterogeneity of hBMSCs, en-
hances the possibility of spontaneous differentiation into
other lineages (Nombela-Arrieta et al., 2011), and may
shorten the cells’ engraftment-activation time (Tsubota
et al., 1999). Therefore, approaches beyond the standard
chemical cocktails have been investigated (Heng et al.,
2004) such as genetic modulation through the overexpres-
sion of genes (e.g., runt-related transcription factor 2,
RUNX2) (Karsenty et al., 2009; Monteiro et al., 2014), and
the use of synthetic/recombinant factors such as bone
morphogenetic protein 4 or cell-derived conditioned me-
dium (CM). Indeed, CM contains an array of growth fac-
tors, cytokines, proteins (Makridakis et al., 2013), and the
recently highlighted extracellular vesicles (EVs) (Collino
et al., 2010). EVs are nanosized particles (exosomes, 30–
100 nm; microvesicles, 50–2000 nm) carrying lipids, pro-
teins, and nucleic acids (Akers et al., 2013). It has been
suggested that hBMSC-secreted EVs include differentiation
cues (miRNA, Collino et al., 2010; Baglio et al., 2015; tRNA,
Baglio et al., 2015; and proteins, Kim et al., 2012), even
upon osteogenic induction (Xu et al., 2014). The regenera-
tive potential of MSC-EVs is supported by preclinical
studies showing the improvement of at least one clinical284 Stem Cell Reports j Vol. 6 j 284–291 j March 8, 2016 j ª2016 The Authooutcome associated with acute kidney/liver/lung injury,
myocardial infarction, or hindlimb ischemia (Akyurekli
et al., 2015). Furthermore, the literature shows that
hBMSCs undergo osteogenic differentiation induced by
EVs derived from monocytes (Ekstrom et al., 2013) or
platelet lysate (Torreggiani et al., 2014). These data enable
us to hypothesize that EVs may be vehicles of communica-
tion toward tissue regeneration. The knowledge on the
bone regenerative potential of hBMSC-EVs is scarce.
Therefore, the purpose of this study is to validate the
functionality of hBMSC-EVs in the osteoinduction of
hBMSCs. We hypothesized that if EVs mirror the
content and fate of parent cells, then EVs derived from os-
teogenically committed hBMSCs will induce the osteo-
genic commitment of homotypic cells without further
supplementation.RESULTS
hBMSCs Exposed to Osteogenic Stimuli Secrete EVs
during Culture
hBMSCs were induced into the osteogenic lineage over
7 days by continuous chemical stimuli provided by stan-
dard osteogenic medium (OM) (Jaiswal et al., 1997) or by
a single genetic stimulus in basal medium (RUNX-2). We
next isolated EVs from the CM of chemically and
genetically induced hBMSCs (OM-EVs and RUNX2-EVs,
respectively) at specific time points using polymeric
precipitation.rs
EVs showed a polydisperse size distribution by dynamic
light scattering (Figure 1A), with polydispersity indexes be-
tween 0.15 and 0.6 (min and max), independently of the
culture conditions and time. The main peak corresponded
to R65% of the population (65.2%–88%, 68.7%–73.5%,
76.2%–84%, min-max for OM-, RUNX2-, basal medium
[BM]-EVs, respectively). Within this population, the diam-
eter of EVs was very homogeneous (31.9–40.2 nm), irre-
spective of culture time or stimulus (Figure 1B). In
contrast, the size of EVs within the second peak (Figure 1A)
ranged between 45 and 348.6 nm. These findings were
corroborated by atomic force microscopy, which showed
a population of intact rounded structures with estimated
desiccated diameters of 32, 40, and 24 nm (Figure 1C,
a–c). On the other hand, as assessed by laser Doppler mi-
cro-electrophoresis, the surface charge of OM-, RUNX2-,
and BM-EVs averaged at 5.2, 6.4, and 5.9 mV,
respectively, and was similar within the different groups
(Figure 1B).
To shed light into the biochemical profile of EVs, we first
used flow cytometry (Figure 1D) to detect the tetraspanins
CD9/63/81, expected to be enriched in EVs fractions
(Lo¨tvall et al., 2014). These analyses showed that EVs
labeled for each of the markers show a distinct positive
shift of the fluorescence signal beyond the non-labeled
controls. Furthermore, the data suggested abundant
CD81-positive and weak CD9-positive EVs populations,
despite the culture conditions (Figure 1D). The presence
of CD63-positive EVs was further confirmed using ELISA
(Figure 1E).
In addition, we aimed at estimating the release of EVs
during culture, based on the normalized number of CD63
particles and total EV protein (Figure 1E). An osteogenic
stimulus-dependent release was observed, differing from
that observed in control conditions. Specifically, while for
OM cultured cells the release of EVs remained at a steady
level over time, for RUNX2 stimulated cells the secretion
of EVs, in terms of total protein, increased over time peak-
ing from the fifth day of culture onward (day 3 versus 5 or
versus 7, p < 0.01; Figure 1E).
Collectively, these results show that hBMSCs secrete
populations of nanosized particles with physical and
biochemical features of EVs, and the yield is regulated by
the osteogenic stimulus provided.
hBMSCs Osteogenically Derived EVs Outperform
Current Strategies to Elicit hBMSCs Osteogenic
Commitment
To test our hypothesis, OM- and RUNX2-EVs were isolated
at set time points during culture (Figure 1E) and used
to sequentially feed uncommitted homotypic hBMSCs,
matching seeding density, culture time, and stimuli
without further supplementation. Therefore, the concen-Stemtration of EVs added to culture mimicked the specific
release of parent cells into the CM.
We first assessed whether EVs could interact and deliver
nucleic acids to homotypic recipient cells. RUNX2-EVs iso-
lated from 1-day cultured cells expressing RUNX2-GFP tag,
were added to uncommitted hBMSCs. After 1 day, the GFP
expression was on average 233-fold greater versus BM in
cells exposed to RUNX2-EVs (6.8–803,min-max), although
at lower levels than that observed for parent cells trans-
fected by lipofection (average 1.6 3 106 fold change, 4 3
104–7 3 106, min-max). This suggests that EVs are able to
interact with the recipient cells and transfer functional
plasmid DNA.
The ability of OM- and RUNX2-EVs to promote the
onset of osteogenesis was examined and compared with
currently available strategies. The differentiation process
is known to impair cell proliferation, due to an increase
in the length of the cell cycle (Roccio et al., 2013), and to
induce changes in the protein synthesis rate (Kristensen
et al., 2013). Therefore, we evaluated the profile of recipient
hBMSC proliferation (Figure 2A) and total protein (Fig-
ure 2B). Notably, a high seeding density was used to ensure
high transfection efficiency. Under these conditions, the
proliferation capacity of OM-EV-treated cells decreased
after day 3 versus BM and OM (Figure 2A), in parallel
with a net protein increase (day 5, versus BM) (Figure 2B).
Furthermore, RUNX2-EV treatment did not impair cell pro-
liferation versus BM, in contrast to parent cells (RUNX2),
attaining proliferation levels higher than those of parent
and OM-EV-exposed cells at the seventh day (Figure 2A),
without major changes in total protein (Figure 2B).
The osteoinductive potential of EVs was then evaluated
in terms of the expression of the extracellular matrix
marker alkaline phosphatase (ALP) (Figure 2C). OM- and
RUNX-2 EVs induced early activation of ALP, in contrast
to that exhibited by the parent cells. Notably, this was
observed in the absence of the mineralization inductors
dexamethasone and b-glycerophosphate (Langenbach
and Handschel, 2013). To better define the osteogenic
commitment of these cells, the temporal gene expression
of osteogenic markers was investigated (Figure 3). OM-EV-
cultured hBMSCs showed early overexpression of the
activator bonemorphogenetic protein 2 (BMP2) (Figure 3C)
by 3- to 6-fold versus BM and OM, and a transient in-
crease in the expression of the Sp7 transcription factor
(osterix) (SP7) (Figure 3B) by 6-fold versus BM at day 3.
Indeed, osteoblastic differentiation is determined by the
overexpression of SP7 (Sinha and Zhou, 2013) through
the BMP-2 signaling cascade (Ulsamer et al., 2008).
Herein, the data suggest early activation of the cascade in-
dependent of the upstream factor RUNX2. In addition,
at early culture times, the downstream factors secreted
phosphoprotein 1 (osteopontin) (SPP1) (Figure 3D) andCell Reports j Vol. 6 j 284–291 j March 8, 2016 j ª2016 The Authors 285
Figure 1. Characterization of Osteogenically Induced hBMSC-EVs
EVs were isolated from the CM of hBMSCs under osteogenic medium (OM) or RUNX2 transcriptionally activated in basal medium (BM,
RUNX2).
(A and B) EV size and charge. Representative size distribution profile highlighting the mean particle diameters (A); and EV size within the
peak with main intensity (left axis) and charge (right axis), shown as the mean ± SEM (three donors, three technical replicates) (B).
(C) EV morphology. Representative atomic force micrographs (top) and graphical representation of individual EV size (a–c) (bottom).
(D) EV enrichment in CD9, CD63, and CD81 analyzed by flow cytometry. Representative histograms of labeled (open peak) and unlabeled
(filled peak) EVs and the median fluorescence intensity ratio (median fluorescence intensity of the detected molecule divided by that of
the non-labeled control), shown as the median (interquartile range [IQR]) (three donors, two technical replicates).
(E) EV yield in terms of normalized CD63-positive EVs (left axis) and normalized total EV protein (right axis), shown as the mean ± SEM
(three donors, two and three technical replicates, respectively). a denotes significant differences compared with BM.
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Figure 2. Effect of Osteogenically Induced hBMSC-EVs on the
Biochemical Parameters of Homotypic Cells
EVs derived from hBMSCs under osteogenic medium (OM), OM-EVs,
or RUNX2 transcriptionally activated in basal medium (BM), RUNX2-
EVs, were transferred to uncommitted hBMSCs without further
supplementation. Cell lysates (A) DNA concentration, (B) normal-
ized protein, (C) normalized ALP activity are shown as Tukey box-
plots (three donors, three technical replicates). The black dots
denote outliers; letters denote significant differences compared
with: a, BM; b, OM; c, RUNX2; b, OM-EVs.integrin-binding sialoprotein (bone sialoprotein) (IBSP)
(Figure 3E) were strongly upregulated (approximately 25-
fold and 7-fold, respectively) in comparison with BM.
Furthermore, RUNX2-EV-cultured hBMSCs showed lower
mRNA RUNX2 levels than those of parent cells stimulated
to overexpress this gene, but similar to that observed in
BMorOM (Figure 3A). As observed forOM-EVs, at early cul-
ture times, RUNX2-EVs induced the overexpression of
BMP2 by 3- to 8-fold (versus BM and OM) (Figure 3C) and
that of SP7 by 8-fold (versus BM) (Figure 3B), indispensable
for progression onto the osteogenic lineage. Also consis-
tent with osteogenic activation, the expression levels ofStemSPP1 (Figure 3D), and importantly those of bone g-carbox-
yglutamate (gla) protein (osteocalcin) (BGLAP) (Figure 3F)
were increased by 48- and 2-fold versus OM and/or BM,
respectively. However, IBSP expression (Figure 3E) was
only slightly increased on the first day of culture (versus
BM, p = 0.02), whereas collagen type I alpha 1 (COL1A1)
expression (Figure 3G) remained at the BM level although
at higher levels than those observed for parent cells.
These results show that extracellular signaling derived
from polymeric precipitated EVs obtained during hBMSCs
osteogenic induction provides guidance for osteogenic
lineage progression of homotypic cells.DISCUSSION
Bone regenerative therapies have been challenged by the
limited understanding of the induction of hBMSC fate.
This hinders the clinical translation of the most promising
strategies. For example, genetically modified cells raise
safety, efficacy, and fate issues (Kumar et al., 2008); syn-
thetic/recombinant factors, used at supra-physiological
doses, are associated with severe side effects and high costs
(Jakob et al., 2012); the CM concentration of bio-
therapeutics is low, at least for some applications, and con-
tains medium contaminants, such as phenol red (Tran and
Damaser, 2015).
Our study demonstrates that hBMSCs secrete vesicles
with features of EVs that have osteoinductive potential.
We showed that hBMSCs secrete a population of EVs het-
erogeneous in size, as noted earlier (Sokolova et al., 2011;
Lobb et al., 2015; Van Deun et al., 2014). Although this
can be attributed to the method of EV isolation (Lobb
et al., 2015; Van Deun et al., 2014) or to sample aggrega-
tion, the sizes obtained (Figures 1A–1C) roughly fall within
the range reported for hBMSC-EVs, 47–180 nm (Bian et al.,
2014; Bruno et al., 2013). Consistent withMSCs expressing
CD9 (Chen et al., 2010), CD63 (Stewart et al., 2003), and
CD81 (Lee et al., 2009), EVs also showed these surface
markers (Figures 1D and 1E), suggesting that they origi-
nated at the parent cell plasma membrane lipid rafts
(Tan et al., 2013). Therefore, it is reasonable to accept
that the parent cell source affects the EVs’ surface proteins,
their glycosylation or lipid composition, and consequently
their charge. We found that the surface charge of hBMSC-
EVs was relatively less negative (Figure 1B) than that re-
ported for umbilical cord MSC-EVs, 52 mV (Sokolova
et al., 2011). Furthermore, our data showed that the envi-
ronmental stimuli affect the yield of EVs (Figure 1E) prob-
ably in parallel with cell activation (Figures 2A and 2B).
This is in line with the oxygen-dependent placental secre-
tion of MSC-EVs (Salomon et al., 2013). Due to their
biophysical and biochemical properties, namely the sizeCell Reports j Vol. 6 j 284–291 j March 8, 2016 j ª2016 The Authors 287
Figure 3. Effect of Osteogenically
Induced hBMSC-EVs on Osteogenic Line-
age-Related Markers of Homotypic Cells
EVs derived from hBMSCs under osteogenic
medium (OM), OM-EVs, or RUNX2 transcrip-
tionally activated in basal medium (BM),
RUNX2-EVs, were transferred to uncommit-
ted hBMSCs without further supplementa-
tion. BM was set as control. qPCR data for
relative gene expression of (A and B) tran-
scription factors, (C) effector, and (D–G)
downstream factors, are shown as means ±
SEM (three donors, three technical repli-
cates). Letters denote significant differ-
ences compared with: a, BM; b, OM; c,
RUNX2.(Figures 1A–1C), EVs may interact differentially with cells.
In general, the uptake of EVs is dose, time (Franzen et al.,
2014), and recipient-cell (Feng et al., 2010) dependent,
while the fate of the EV cargo varies with the particle
subtype (Kanada et al., 2015). We indirectly showed that
EVs added in concentrations comparable with those pro-
duced in vitro undergo uptake by hBMSCs, although the
subtype and percentage of EVs being internalized was not
determined.
The exogenous addition of osteogenically derived EVs
outperformed the effect of current osteoinductive strate-
gies in terms of the type and/or intensity of the signaling,
with the early activation of the key osteogenic commit-
ment genes SP7 (Figure 3B) and BMP2 (Figure 3C), consid-
ered necessary and sufficient to induce bone formation
(Noel et al., 2004). In addition, EVs induced a transient
upregulation of downstream matrix-associated genes and288 Stem Cell Reports j Vol. 6 j 284–291 j March 8, 2016 j ª2016 The Authoprotein (Figures 3D, 3E, and 2C) that may be required to
promote cell-cell and cell-matrix interactions and support
long-term differentiation and mineralization (Langenbach
and Handschel, 2013).
Notably, no major differences were noted between the
exogenous addition of OM- or RUNX2-EVs, suggesting
that the inherent cargo of hBMSC-EVs may also contribute
to the observed effect. Indeed, the selective cargo of EVs
derived fromuncommitted hBMSCs suggests their involve-
ment in the osteogenic differentiation. MSC-EVs were
described to carry tRNA species putatively targeting the
transcription factor RUNX2 and SOX11 (Baglio et al.,
2015), miRNA, miR-22, that indirectly targets RUNX2 (Ba-
glio et al., 2015) and several proteins involved in the
BMP, mitogen-activated protein kinase, transforming
growth factor b, and Wnt pathways (Kim et al., 2012).
Furthermore, our experimental design, comprising thers
addition of a pool of OM-/RUNX2-EVs to hBMSCs, does
not exclude the contribution of the EVs derived from recip-
ient cells and a possible synergistic signaling.
Our results show the beneficial effects of cell-secreted fac-
tors, confirming that hBMSCs secrete EVs that are key
players in the modulation of cell fate. We were able to
identify and isolate unique factors that regulate the osteo-
genic commitment. Therefore, EVs are potential cell-free/
secretome-based therapies for gene delivery applications
that may circumvent the risks associated with current ther-
apies and provide greater safety and efficacy benefits.EXPERIMENTAL PROCEDURES
hBMSC Isolation and Culture
hBMSCs were obtained from three patients (aged 55, 68, and 71
years) after informed consent, as approved by the Ethical Commit-
tee of the Hospital Center of Alto Ave, Guimara˜es, under the Coop-
eration Agreement established between the 3B’s Research Group,
University of Minho and this hospital. hBMSCswere characterized
and cultured using our standard protocols (Monteiro et al., 2014).
Osteogenic Commitment of Chemically and
Genetically Induced hBMSCs
The following experimentswere carried out usingminimumessen-
tial medium alphamediumwith fetal bovine serum depleted from
EVs (Thery et al., 2006). The osteogenic commitment of adhered
hBMSCs (passage 4; 750 cells/coverslip mm2; 1 ml/well) was
induced by chemical stimuli (BM with 108 M dexamethasone,
50 mg/ml ascorbic acid, and 0.01 M b-glycerophosphate; Sigma);
or by genetic modulation (RUNX2 cationic-lipid transfection in
BM). The transfection mixture comprised 500 ng of plasmid
DNA and a lipid-DNA ratio of 23 (Lipofectamine LTX with Plus
Reagents, Alfagene, Life Technologies). After 5 hr the transfection
mixture was replaced by 1 ml of BM. The transfection efficiency
was evaluated by GFP reporter gene expression, showing a tran-
sient overexpression of RUNX2 (Figure S1). See Supplemental
Experimental Procedures for additional details. hBMSCs cultured
in BM were set as control. For all the conditions, the CM was har-
vested at 1, 3, 5, and 7 days. The cells were rinsed, immersed in 1ml
of water or 0.8 ml of Tri-reagent (Sigma) and stored at 80C.
Isolation of EVs
EVs were isolated from CM using a polymeric precipitation solu-
tion (ExoQuick-TC; System Biosciences, BioCat) according to the
manufacturer’s instructions. See Supplemental Experimental Pro-
cedures for additional details, including validation (Figure S2).
Characterization of Osteogenically Induced
hBMSC-EVs
EV size was evaluated by DLS, charge by laser Doppler micro-elec-
trophoresis (Malvern Nano ZS), and morphology by AFM (Dimen-
sion Icon, Bruker) at 15 mg of total protein/ml. EV total protein was
evaluated by Micro BCA (Fisher Scientific) and CD63 by ELISA
(EXOEL CD63, System Biosciences), according to the manufac-Stemturer’s instructions; and CD9/63/81 by flow cytometry (Lasser
et al., 2012). See Supplemental Experimental Procedures for addi-
tional details.
Transfer of Osteogenically Induced hBMSC-EVs into
Uncommitted Homotypic Cells
Adhered hBMSCs (passage 4; 750 cells/coverslip mm2; 1 ml/well)
were fed with BM containing EVs derived from osteogenically
induced hBMSCs after 1 day of culture, matching the seeding
density. At days 1, 3, and 5 the recipient cells were fedwith BMcon-
taining EVs derived from osteogenically induced hBMSCs, match-
ing the seeding density, culture time, and stimuli. Cells were
retrieved at 1, 3, 5, and 7 days and processed as the EV parent cells.
Cellular Biochemistry Analyses
Cell proliferation was evaluated by DNA quantification (Quant-iT
PicoGreen dsDNA assay, Invitrogen, Alfagene), cellular protein by
Micro BCA assay, according to the manufacturer’s instructions;
and alkaline phosphatase specific activity by a colorimetric assay
(Monteiro et al., 2014). The number of hBMSCs was estimated
based on an experimental standard curve (DNA = 0.0017 3 cell
number + 95.25, R2 = 0.98).
Gene Expression Analyses
Total RNA was isolated and reverse transcribed into cDNA (qScript
cDNA synthesis kit, Quanta BioSciences, VWR), followed by qPCR
(PerfeCTa SYBR Green FastMix, Quanta BioSciences), according to
the manufacturer’s instructions. See Supplemental Experimental
Procedures for additional details.
Statistical Analyses
Data normality was evaluated by the D’Agostino-Pearson test.
A non-parametric Kruskal-Wallis test was applied followed by
Dunn’s test for multiple comparisons (GraphPad, version 6.0). Sta-
tistical significance was defined at p < 0.01.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, two figures, and one table and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2016.01.001.
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